PTAB invalidates Johnson & Johnson cancer drug patent

The Patent Trial and Appeal Board (PTAB) has invalidated a Johnson & Johnson (J&J) patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J unit accuses rival of ‘shocking’ trade secrets theft

11 February 2021 A Johnson & Johnson unit has accused eye care product manufacturer Alcon of trade secrets theft, alleging that it had perpetrated “piracy of a nearly unfathomable scale” in ripping off a computer code.

Biotechnology

PTAB blocks Qiagen’s bid to invalidate diagnostics patent

20 July 2020 Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

16 May 2019 The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.